Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati, Eva Hellström‐Lindberg, David Bowen, et al.
Blood (2013) Vol. 122, Iss. 17, pp. 2943-2964
Open Access | Times Cited: 635

Showing 1-25 of 635 citing articles:

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma, Rafael Bejar, Siddhartha Jaiswal, et al.
Blood (2015) Vol. 126, Iss. 1, pp. 9-16
Open Access | Times Cited: 1720
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Torsten Haferlach, Yasunobu Nagata, Vera Grossmann, et al.
Leukemia (2013) Vol. 28, Iss. 2, pp. 241-247
Open Access | Times Cited: 1420
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 2, pp. 140-151
Open Access | Times Cited: 449
Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes
Yasunobu Nagata, Vera Grossmann, Yusuke Okuno, et al.
Blood (2013) Vol. 122, Iss. 21, pp. 521-521
Open Access | Times Cited: 431
Clinical significance of somatic mutation in unexplained blood cytopenia
Luca Malcovati, Anna Gallí, Erica Travaglino, et al.
Blood (2017) Vol. 129, Iss. 25, pp. 3371-3378
Open Access | Times Cited: 426
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, et al.
Blood (2015) Vol. 126, Iss. 2, pp. 233-241
Open Access | Times Cited: 399
Myelodysplastic Syndromes
Mario Cazzola
New England Journal of Medicine (2020) Vol. 383, Iss. 14, pp. 1358-1374
Closed Access | Times Cited: 369
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Théo de Witte, David Bowen, Marie Robin, et al.
Blood (2017) Vol. 129, Iss. 13, pp. 1753-1762
Open Access | Times Cited: 338
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
Uwe Platzbecker, Ulrich Germing, Katharina S. Götze, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 10, pp. 1338-1347
Closed Access | Times Cited: 273
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia
Luca Malcovati, Elli Papaemmanuil, Ilaria Ambaglio, et al.
Blood (2014) Vol. 124, Iss. 9, pp. 1513-1521
Open Access | Times Cited: 235
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
Matteo Giovanni Della Porta, Anna Gallí, Andrea Bacigalupo, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 30, pp. 3627-3637
Open Access | Times Cited: 230
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Matti Aapro, Yves Béguin, Carsten Bokemeyer, et al.
Annals of Oncology (2017) Vol. 29, pp. iv96-iv110
Open Access | Times Cited: 229
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Nicolaus Kröger, Simona Iacobelli, Georg‐Nikolaus Franke, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 19, pp. 2157-2164
Open Access | Times Cited: 219
Treatment of MDS
Uwe Platzbecker
Blood (2019) Vol. 133, Iss. 10, pp. 1096-1107
Open Access | Times Cited: 195
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 11, pp. 1223-1233
Open Access | Times Cited: 172
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia
Yusuke Shiozawa, Luca Malcovati, Anna Gallí, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 165
Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
Nicola Guzzi, Sowndarya Muthukumar, Maciej Cieśla, et al.
Nature Cell Biology (2022) Vol. 24, Iss. 3, pp. 299-306
Open Access | Times Cited: 80
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. 2827-2842
Open Access | Times Cited: 66
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
Matteo Giovanni Della Porta, Emilio Paolo Alessandrino, Andrea Bacigalupo, et al.
Blood (2014) Vol. 123, Iss. 15, pp. 2333-2342
Open Access | Times Cited: 171
Recent developments in myelodysplastic syndromes
Rafael Bejar, David P. Steensma
Blood (2014) Vol. 124, Iss. 18, pp. 2793-2803
Open Access | Times Cited: 166
Time-dependent changes in mortality and transformation risk in MDS
Michael Pfeilstöcker, Heinz Tuechler, Guillermo Sanz, et al.
Blood (2016) Vol. 128, Iss. 7, pp. 902-910
Open Access | Times Cited: 164
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pierre Fenaux, Dagmar Haase, Guillermo Sanz, et al.
Annals of Oncology (2014) Vol. 25, pp. iii57-iii69
Open Access | Times Cited: 153
Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort
Reinhard Stauder, Veronika Bach, Guenter Schruckmayr, et al.
Clinical Interventions in Aging (2014), pp. 1187-1187
Open Access | Times Cited: 149
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
Matteo Giovanni Della Porta, Erica Travaglino, Emanuela Boveri, et al.
Leukemia (2014) Vol. 29, Iss. 1, pp. 66-75
Closed Access | Times Cited: 144
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti, et al.
Leukemia (2018) Vol. 32, Iss. 12, pp. 2648-2658
Open Access | Times Cited: 142
Page 1 - Next Page

Scroll to top